Abiopharma

🔍 ROTHBLATT MARTINE A (Executive)

Company: UNITED THERAPEUTICS Corp (UTHR)

Report Date: 2026-04-16

Detailed Transactions and Holdings:

• Acquired 9,500 shares of Common Stock at $146.03 per share (Direct)
  Date: 2026-04-16 | Code: M | equity_swap_involved: false | shares_owned_after: 50,013.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 400 shares of Common Stock at $573.9595 per share (Direct)
  Date: 2026-04-16 | Code: S | equity_swap_involved: false | shares_owned_after: 49,613.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,800 shares of Common Stock at $574.7892 per share (Direct)
  Date: 2026-04-16 | Code: S | equity_swap_involved: false | shares_owned_after: 47,813.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 930 shares of Common Stock at $575.9883 per share (Direct)
  Date: 2026-04-16 | Code: S | equity_swap_involved: false | shares_owned_after: 46,883.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 2,048 shares of Common Stock at $577.0326 per share (Direct)
  Date: 2026-04-16 | Code: S | equity_swap_involved: false | shares_owned_after: 44,835.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 2,027 shares of Common Stock at $578.0501 per share (Direct)
  Date: 2026-04-16 | Code: S | equity_swap_involved: false | shares_owned_after: 42,808.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 1,750 shares of Common Stock at $579.3649 per share (Direct)
  Date: 2026-04-16 | Code: S | equity_swap_involved: false | shares_owned_after: 41,058.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 385 shares of Common Stock at $579.8397 per share (Direct)
  Date: 2026-04-16 | Code: S | equity_swap_involved: false | shares_owned_after: 40,673.00 | transaction_form_type: 4 | Footnotes: F1, F8
• Sold 160 shares of Common Stock at $581.3325 per share (Direct)
  Date: 2026-04-16 | Code: S | equity_swap_involved: false | shares_owned_after: 40,513.00 | transaction_form_type: 4 | Footnotes: F1, F9
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-16 | Code: H | nature_of_ownership: by Spouse | shares_owned_after: 166.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-16 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 324,443.00 | Footnotes: F10
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-16 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 258,117.00 | Footnotes: F11
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-16 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 45,596.00 | Footnotes: F12
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-16 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 10,962.00 | Footnotes: F13
• Sold 9,500 shares of Stock Option at $146.03 per share (Derivative)
  Date: 2026-04-16 | Code: M | Expires: 2027-03-15 | Exercise: 2020-03-15 | equity_swap_involved: false | shares_owned_after: 26,500.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.
• F10: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
• F11: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
• F12: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
• F13: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
• F2: This transaction was executed in multiple trades at prices ranging from $573.24 to $574.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F3: This transaction was executed in multiple trades at prices ranging from $574.28 to $575.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F4: This transaction was executed in multiple trades at prices ranging from $575.54 to $576.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F5: This transaction was executed in multiple trades at prices ranging from $576.56 to $577.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F6: This transaction was executed in multiple trades at prices ranging from $577.56 to $578.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F7: This transaction was executed in multiple trades at prices ranging from $578.665 to $579.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F8: This transaction was executed in multiple trades at prices ranging from $579.69 to $580.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F9: This transaction was executed in multiple trades at prices ranging from $580.76 to $581.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.